Hemostemix Inc. (CVE:HEM – Get Free Report) shares dropped 22.9% on Thursday . The company traded as low as C$0.18 and last traded at C$0.19. Approximately 504,239 shares traded hands during mid-day trading, a decline of 5% from the average daily volume of 530,580 shares. The stock had previously closed at C$0.24.
Hemostemix Stock Up 5.4 %
The firm has a market cap of C$28.42 million, a price-to-earnings ratio of -5.69 and a beta of 0.20. The firm has a fifty day simple moving average of C$0.19 and a 200-day simple moving average of C$0.11. The company has a debt-to-equity ratio of -55.07, a quick ratio of 0.48 and a current ratio of 0.04.
Hemostemix Company Profile
Hemostemix Inc, a clinical stage biotechnology company, develops, manufactures, and commercializes blood-derived stem cell therapies for medical conditions in Canada. Its lead product is ACP-01, an autologous cell therapy, which is in Phase II clinical trial for the treatment of vascular diseases, such as cardiovascular disease, peripheral arterial disease, angina pectoris, and ischemia.
Featured Articles
- Five stocks we like better than Hemostemix
- Utilities Stocks Explained – How and Why to Invest in Utilities
- Roblox’s Big Dip: A Chance to Get in on the Vaunted Gaming Stock?
- 3 Best Fintech Stocks for a Portfolio Boost
- 3 Dividend ETFs to Capitalize on the Slide in Chip Stocks
- Why Are These Companies Considered Blue Chips?
- Is Chevron Stock Primed for Growth After Profit-Boosting News?
Receive News & Ratings for Hemostemix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hemostemix and related companies with MarketBeat.com's FREE daily email newsletter.
